Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

VNDA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Vanda Pharmaceuticals Inc.NASDAQ: VNDA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 90.0%

Gross margin was 90.0% in Q1 FY2026, down 2.9 pp from a year earlier. On a trailing-twelve-month basis it was 92.5%, down 1.0 pp year over year. Over 3 fiscal years it widened by 3.5 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
90.0%-3.3 pp QoQ
Last fiscal yearDec 2025
94.0%-0.3 pp YoY
LTMMar 2026
92.5%-1.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.9 pp——
1 year-0.3 pp——
3 years+3.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
94.0%
Year-over-year change
-0.3pp

Gross Margin vs competitors

How VNDA compares with its peers on the latest reported figures

  • VNDA's LTM Mar 2026 gross margin of 92.5% is the highest of the 5 companies compared; the peer median is -342.3%.
  • Its year-over-year change of -1.0 pp is the 2nd highest of 5, against a peer median of -353.4 pp.
  • Over three fiscal years its change of +3.5 pp compares with a peer median of -4.5 pp.
VNDA Competitors Peer median
Gross Margin for VNDA and competitors
Company Period LTM level YoY 3-year change
VNDAVanda Pharmaceuticals Inc.LTM Mar 202692.5% -1.0 pp+3.5 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202691.2% -8.8 pp-4.5 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-86.7% +2.3 pp+136.3 pp
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-598.0% -698.0 pp—
HUMAHumacyte, Inc.LTM Mar 2026-748.5% -729.4 pp-309.0 pp
ACHVAchieve Life Sciences, Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
SGMTSagimet Biosciences Inc.FY2025— ——
ALLOAllogene Therapeutics, Inc.FY2025— ——
IMRXImmuneering CorporationFY2025— ——
Peer median (excluding VNDA) -342.3%-353.4 pp-4.5 pp

Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue268.68M254.38M192.64M198.77M216.11M
Cost of Revenue25.63M24.28M14.8M11.31M13.04M
Gross Profit243.05M230.1M177.84M187.46M203.06M
Gross Margin90.5%90.5%92.3%94.3%94.0%
Research & Development75.36M85.77M76.82M74.43M109.27M
Selling, General & Admin124.05M136.49M112.88M146.41M237.95M
Operating Expenses200.89M223.77M191.8M228.12M354.23M
Depreciation & Amortization2.84M2.73M3.01M8.13M11.92M
EBITDA45.21M14.03M9.35M(14.79M)(126.73M)
EBITDA Margin16.8%5.5%4.9%-7.4%-58.6%
Operating Income42.17M6.33M(13.95M)(40.66M)(151.17M)
Operating Margin15.7%2.5%-7.2%-20.5%-70.0%
Interest Income199K0000
Interest Expense00000
Other Income / Expenses199K4.97M20.29M17.74M12.52M
Income Before Tax42.36M11.3M6.34M(22.92M)(138.65M)
Pre-Tax Margin15.8%4.4%3.3%-11.5%-64.2%
Income Tax Expense9.21M5.03M3.83M(4.02M)81.83M
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Net Margin12.3%2.5%1.3%-9.5%-102.0%
EPS (Basic)0.600.110.04(0.32)(3.74)
EPS (Diluted)0.580.110.04(0.32)(3.74)
Weighted Avg Shares55.55M56.46M57.38M58.15M58.93M
Weighted Avg Shares (Diluted)56.92M56.98M57.56M58.15M58.93M

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Intrinsic Alpha fair value

Locked

Current Price

$3.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.